The information on this website is not intended for diagnosis or treatment. Please consult your physician for health concerns.

+90 850 321 50 00

Ide-cel and Cilta-cel CAR-T Therapy for Advanced Multiple Myeloma

BCMA-targeted chimeric antigen receptor T-cell therapy with idecabtagene vicleucel and ciltacabtagene autoleucel for relapsed refractory multiple myeloma

Written by: Saygı Hospital Health Guide Editorial Board
Last updated:

This content has been compiled by the Saygı Hospital Health Guide Editorial Board and is periodically reviewed by a specialist physician.

References (5)

This content is for informational purposes only and does not constitute medical advice. You can book an appointment at our Hematoloji department. Book Appointment →

What is Ide-cel and Cilta-cel CAR-T Therapy for Advanced Multiple Myeloma?

Ide-cel and cilta-cel are FDA-approved BCMA-targeted CAR-T cell therapies for relapsed refractory multiple myeloma.

Both target B-cell maturation antigen on plasma cells with cilta-cel utilizing dual epitope binding.

Pivotal trials showed 73% response rate for ide-cel and 98% for cilta-cel in heavily pretreated patients.

Median progression-free survival exceeds 1 year for ide-cel and 2 years for cilta-cel.

Cilta-cel has shown movement disorders and other delayed neurotoxicity requiring monitoring.

Symptoms

Cytokine release syndrome with fever, hypotension, hypoxia requires tocilizumab and supportive care.
Immune effector cell-associated neurotoxicity syndrome with confusion, seizures requires monitoring.
Prolonged cytopenias requiring growth factor support and transfusions.
Infections including viral, bacterial, fungal opportunistic infections require prophylaxis and monitoring.
Movement disorders with cilta-cel including parkinsonian features require recognition and management.

Risk Factors

Multiple myeloma with prior exposure to immunomodulatory drugs, proteasome inhibitors, anti-CD38 antibodies.
Triple-class refractory disease defines patients with very limited treatment options.
Adequate organ function and performance status required for safe CAR-T administration.
Prior BCMA-directed therapy may affect response to CAR-T therapy.
Extramedullary disease may have lower response rates compared to medullary disease.

When to See a Doctor?

If you experience any of the following symptoms, seek medical attention promptly:

  • Multiple myeloma patients with relapsed disease after multiple prior therapies warrant CAR-T evaluation.
  • Specialized CAR-T cell therapy center referral with multidisciplinary expertise essential.
  • Severe cytokine release syndrome, neurotoxicity, infections require urgent intensive care.
  • Prolonged cytopenias, persistent infections require ongoing intensive supportive care.
  • Disease relapse after CAR-T may warrant alternative therapies including bispecific antibodies.

Treatment Methods

01
Lymphodepletion chemotherapy with fludarabine and cyclophosphamide before CAR-T infusion.
02
Single CAR-T infusion of ide-cel 300-460 million cells or cilta-cel 0.5-1.0 million cells/kg.
03
Cytokine release syndrome management with tocilizumab and corticosteroids.
04
Neurotoxicity management with corticosteroids and supportive care.
05
Comprehensive multidisciplinary care with specialized CAR-T cell therapy center, CAR-T administration with monitoring for at least 4 weeks, intensive supportive care including infection prophylaxis with antiviral, antibacterial, antifungal agents, monitoring for prolonged cytopenias requiring growth factor support and transfusions, immunoglobulin replacement for hypogammaglobulinemia, post-CAR-T disease surveillance, salvage therapy planning for relapse including bispecific antibodies and clinical trials, multidisciplinary care for delayed adverse events, and survivorship care addressing long-term effects of CAR-T therapy provides transformative outcomes for patients with relapsed refractory multiple myeloma.

Which Department to Visit?

You can visit our Hematoloji department for these complaints. Our specialist physicians will create the most suitable treatment plan for you.

Learn About Hematoloji Department

Let us help you

You can make an appointment with our specialists or contact us for your concerns.

Book AppointmentContact Us

Related Health Topics

Other articles from the same department you may want to explore.

Anaemia

Dahiliye (İç Hastalıkları)

Anaemia is a low haemoglobin level that reduces oxygen delivery, causing fatigue, pallor, and shortness of breath. It is not a disease itself but a sign of many underlying conditions. Most cases are correctable with appropriate diagnosis and treatment.

Iron Deficiency Anaemia

Dahiliye (İç Hastalıkları)

Iron deficiency anaemia develops when dietary intake, absorption, or losses create an iron shortfall, most often affecting women and children. Identifying the underlying cause is the core of management, alongside iron replacement.

Vitamin B12 Deficiency

Dahiliye (İç Hastalıkları)

Vitamin B12 deficiency can cause megaloblastic anaemia, neurological symptoms, and cognitive impairment. Early treatment with intramuscular or oral B12 largely prevents irreversible complications.

Hypertension (High Blood Pressure) Management

Dahiliye (İç Hastalıkları)

Hypertension is often called the silent killer because it progresses symptom-free for years and can damage the heart, brain, kidneys, and eyes. Regular monitoring, lifestyle change, and evidence-based drug therapy dramatically reduce cardiovascular risk.

Chronic Kidney Disease

Dahiliye (İç Hastalıkları)

Chronic kidney disease is one of the most common complications of chronic conditions such as diabetes and hypertension, and can be silent in its early stages.

Hepatitis B (HBV)

Dahiliye (İç Hastalıkları)

Hepatitis B is a DNA virus infection causing acute and chronic hepatitis with risk of cirrhosis and hepatocellular carcinoma; diagnosis integrates HBsAg, HBeAg, anti-HBc, and HBV DNA with management based on disease phase using nucleos(t)ide analogues (entecavir, tenofovir) and universal infant vaccination.

Hepatitis C (HCV)

Dahiliye (İç Hastalıkları)

Hepatitis C is an RNA virus causing chronic hepatitis that may progress to cirrhosis and hepatocellular carcinoma; modern direct-acting antiviral (DAA) pangenotypic regimens (sofosbuvir/velpatasvir, glecaprevir/pibrentasvir) achieve sustained virologic response over 95% in 8–12 weeks with universal adult screening and cure for nearly all patients.

Fatty Liver Disease

Dahiliye (İç Hastalıkları)

Non-alcoholic fatty liver disease (NAFLD) is closely related to obesity and metabolic syndrome and is largely reversible with early treatment.

Health Disclaimer: The information on this page is prepared for general informational purposes only. It does not replace medical diagnosis and treatment. Please consult your physician for your complaints. Saygı Hospital does not accept responsibility for actions taken based on the information on this page.